Anti-glaucoma eye drops linked to meibomian gland changes

Article

The long-term use of anti-glaucoma eye drops is linked to changes in meibomian gland morphology and function.

The long-term use of anti-glaucoma eye drops is linked to changes in meibomian gland morphology and function, according to a paper published in the journal Cornea.

Dr Reiko Arita et al., Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, studied 71 eyes of 71 glaucoma patients who were administered one type of anti-glaucoma eye drops (group 1), 61 eyes of 61 glaucoma patients (group 2) receiving two types of anti-glaucoma eye drops and 30 eyes of 30 glaucoma patients (group 3) receiving three types of anti-glaucoma eye drops. There was also a control group consisting of 75 eyes of 75 healthy participants.

Noncontact meibography was used to observe and score the meibomian glands of upper and lower eyelids. Slit lamp examination was used to evaluate lid margin and superficial punctate keratopathy, whilst a questionnaire was used to evaluate subjective symptoms. Tear film break-up time (TBUT) was assessed, along with meibum.

Glaucoma patients demonstrated significantly higher lid margin abnormality, superficial punctate keratopathy, meiboscore and meibum scores, compared to control participants. TBUT and Schirmer scores were significantly lower for glaucoma patients, compared to the control group.

It was found that meiboscore significantly correlated with lid margin abnormality score and TBUT in group 1, TBUT, symptom score and age in group 2 and lid margin abnormality score only in group 3.

For the abstract please click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.